Labcorp Raises Full-Year Guidance, Roche VENTANA BAP1 Mesothelioma Test, SEKISUI OSOM Combo Clearance — Oct 28, 2026

The Diagnostics & Lab Testing Business Brief · Oct 28, 2026 · 6m

The Diagnostics & Lab Testing Business Brief — Wednesday, October 28, 2026

The business behind the tests. Today's developments shaping the diagnostics industry.

Labcorp Q3 2026 results; guidance raised: announced Oct 28, 2026 — revenue $3.81 billion (+6.9%), diluted EPS $3.22 (+3.3%), adjusted EPS $4.78 (+14.5%); Diagnostics Laboratories revenue +6.5%, Biopharma Laboratory Services +8.5%. Full-year guidance raised: revenue growth 5.9%–6.7%, adjusted EPS $18.30–$18.70. FDA approval of PGDx elio® tissue complete CDx for advanced melanoma; post-quarter acquisition agreements for select…